TickerSpark Feed

pharmaceuticals

Everything tagged "pharmaceuticals" across the TickerSpark archives.

Regeneron Pharmaceuticals (REGN): Dupixent Growth Offsets EYLEA Risk

Regeneron earns a Buy on strong Dupixent momentum, rising free cash flow, and a valuation that still leaves room for upside. EYLEA erosion remains the key offset, but the pipeline and capital returns support the medium-term case.

Jul 29, 2026·23 MIN

Healthcare Biotechnology Biotech

← Previous

Page 2 of 2

On-Demand Research

Need research on a stock not covered here?

Generate AI research on any ticker — grades, price targets, and full analysis in minutes.

Open the Generator

For Active Investors

Stock research for every investor

Reports on any stock
Daily market intelligence
AI analyst in your pocket
Portfolio analysis tools

Get Full Access →

Cancel anytime

Today's Top MoverCHTR

▲10.61%

Charter Communications, Inc. · $134.06

Regeneron Pharmaceuticals (REGN): Dupixent Growth Offsets EYLEA Risk

Need research on a stock not covered here?

A new stock idea, every evening.

Stock research for every investor